Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which completed Phase II clinical trial for the treatment of peripheral arterial disease, chronic limb threatening ischemia, cardiovascular ischemia and angina, and vascular dementia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
Frequently asked questions
What sector does Hemostemix Inc (HMTXF) operate in?
Hemostemix Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Hemostemix Inc (HMTXF) current stock price?
As of the latest data, Hemostemix Inc stock price is $0.04, with a previous close of $0.04.
What is Hemostemix Inc (HMTXF) current market capitalization?
Hemostemix Inc market cap is approximately 8.65 million.
What is Hemostemix Inc (HMTXF) Earnings Per Share (EPS)?
The trailing EPS is -$0.02.
What is Hemostemix Inc (HMTXF) EBITDA?
Hemostemix Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -402.53 thousand.
Does Hemostemix Inc (HMTXF) pay dividends?
No. Hemostemix Inc does not pay a dividend.
What is Hemostemix Inc (HMTXF) beta (volatility) score?
Hemostemix Inc has a beta of 0.732, indicating lower volatility than the overall market.